# Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes

> **NCT03226210** · PHASE4 · COMPLETED · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 110 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** aspart insulin or lipro insulin

## Key facts

- **NCT ID:** NCT03226210
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-01
- **Primary completion:** 2016-05-01
- **Final completion:** 2016-07-01
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226210, "Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03226210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*